Prescribing Information
Composition:
Dasanix : Each tablet contains Dasatinib 100mg
Dasanix50 : Each tablet contains Dasatinib 50mg
Dasanix20 : Each tablet contains Dasatinib 20mg
Clinical Pharmacology:
Dasatinib is an oral BCR-ABL tyrosine kinase inhibitor (inhibits the “Philadelphia chromosome”) and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML)and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.